{"entity":{"id":"idea-tr1-aggressive-futility-boundaries","kind":"idea","name":"Stop failing trials earlier with pre-registered aggressive futility rules","aka":[],"tldr":"Large phase 3 trials often continue for years after interim data show the drug is unlikely to work. Pre-registering futility boundaries at 30 to 50 percent of the information, judged by independent committees and reported publicly, would stop them earlier, sparing patients and freeing money for better ideas.","summary":"Phase 3 protocols include non-binding but pre-registered futility boundaries at 30-50 percent information (predictive probability of success below a threshold), evaluated by independent monitoring committees, with public reporting of the interim decision. Sponsors commit to the rule in the registry entry, reducing the temptation to continue for commercial reasons.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Trial design, endpoints and cost): Davis et al., Availability of evidence of benefits on survival and quality of life of cancer drugs approved by EMA 2009-13 (BMJ 2017)","url":"https://doi.org/10.1136/bmj.j4530"}],"tags":[],"related":["clinicaltrials-gov"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-trial-design","b-negative-results","b-funding-allocation"],"keyPapers":["paper-davis-bmj"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Trials with pre-registered aggressive futility rules will stop negative studies a median of 12 months earlier and expose 30 percent fewer patients to ineffective experimental arms, with a negligible increase in falsely abandoned effective drugs.","rationale":"Retrospective analyses of negative phase 3 trials show most would have met conventional futility criteria at interim, yet sponsors often lack pre-specified rules or set them conservatively.","test":"Simulate aggressive futility rules on completed negative phase 3 trials with interim data available and quantify time and patients saved versus false stops of positive trials.","maturity":"speculative","actor":"industry","cost":"small","horizonYears":2},"route":"/ideas/idea-tr1-aggressive-futility-boundaries/","neighbours":{"collection":[{"id":"clinicaltrials-gov","kind":"collection","name":"ClinicalTrials.gov","route":"/collections/clinicaltrials-gov/"}],"bottleneck":[{"id":"b-negative-results","kind":"bottleneck","name":"Failures are hidden","route":"/bottlenecks/b-negative-results/"},{"id":"b-funding-allocation","kind":"bottleneck","name":"Funding follows fashion, not burden","route":"/bottlenecks/b-funding-allocation/"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/"}],"paper":[{"id":"paper-davis-bmj","kind":"paper","name":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13","route":"/key-papers/paper-davis-bmj/"}]}}